Patient-Reported Distress in Myelodysplastic Syndromes and Its Association With Clinical Outcomes: A Retrospective Cohort Study

Restricted access

Background: NCCN defines distress as a multifactorial, unpleasant emotional experience of a psychological nature that may interfere with patients' ability to cope with cancer symptoms and treatment. Patients with myelodysplastic syndromes (MDS) are at risk for distress due to the largely incurable nature of this hematopoietic malignancy and its symptom burden, yet associations with clinical outcomes are unknown. Methods: We retrospectively reviewed patient-reported distress data from adult ambulatory patients with MDS visiting a single, tertiary care medical center from July 2013 to September 2015. Demographic, diagnostic, treatment, and comorbidity information were abstracted from records along with NCCN Distress Thermometer (DT) and Problem List (PL) scores. Survival was analyzed using the Kaplan-Meier method and Cox proportional hazards regression. Results: We abstracted 376 DT scores (median, 1; range, 0–10) from 606 visits and 110 patients (median, 2 DT scores/patient; range, 1–16). NCCN Guidelines suggest that patients with DT scores ≥4 should be evaluated for referral to specialty services to address unmet needs. A total of 54 patients (49%) had at least 1 DT score ≥4 and 20 (18%) had 2 or more DT scores ≥4; 98 patients (89.1%) reported 1,379 problems during 23,613 person-days of follow-up (median, 4 problems/patient/visit; range, 1–23). The 5 most frequently reported problems were fatigue (181 times; 78 patients), pain (95 times; 46 patients), worry (80 times; 45 patients), sleep (78 times; 41 patients), and tingling hands/feet (68 times; 33 patients). After adjustment for risk stratification at diagnosis, a single point increase on the DT was associated with an increased risk of death (hazard ratio, 1.18; 95% CI, 1.01–1.36). Conclusions: Patients with MDS experience a high burden of distress, and patient-reported distress is associated with clinical outcomes. Distress should be further studied as a prognostic variable and a marker of unmet needs in MDS.

Author contributions: Study concept and design: Troy, de Castro, Samsa, Abernethy, LeBlanc. Data acquisition: Troy, Pupa, LeBlanc. Data analysis: Troy. Initial manuscript draft: Troy. Critical revision of statistical analyses: Samsa. Data interpretation: All authors. Writing of manuscript: All authors.

Correspondence: Thomas W. LeBlanc, MD, MA, MHS, Duke University School of Medicine, Department of Medicine, Division of Hematological Malignancies and Cellular Therapy, Box 2715, Durham, NC 27710. E-mail: thomas.leblanc@duke.edu
  • 1.

    VanHoose L, Black LL, Doty K. An analysis of the distress thermometer problem list and distress in patients with cancer. Support Care Cancer 2015;23:12251232.

    • Search Google Scholar
    • Export Citation
  • 2.

    Holland JC, Deshields TL, Andersen B. NCCN Clinical Practice Guidelines in Oncology: Distress Management. Version 1.2018. Accessed January 31, 2018. To view the most recent version of these guidelines, visit NCCN.org.

    • Search Google Scholar
    • Export Citation
  • 3.

    Zabora J, BrintzenhofeSzoc K, Curbow B. The prevalence of psychological distress by cancer site. Psychooncology 2001;10:1928.

  • 4.

    Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602606.

    • Search Google Scholar
    • Export Citation
  • 5.

    Brown KW, Levy AR, Rosberger Z, Edgar L. Psychological distress and cancer survival: a follow-up 10 years after diagnosis. Psychosom Med 2003;65:636643.

    • Search Google Scholar
    • Export Citation
  • 6.

    Pirl WF, Greer JA, Traeger L. Depression and survival in metastatic non-small-cell lung cancer: effects of early palliative care. J Clin Oncol 2012;30:13101315.

    • Search Google Scholar
    • Export Citation
  • 7.

    Troy JD, Atallah E, Geyer JT, Saber W. Myelodysplastic syndromes in the United States: an update for clinicians. Ann Med 2014;46:283289.

  • 8.

    Heptinstall K. Quality of life in myelodysplastic syndromes. A special report from the Myelodysplastic Syndromes Foundation, Inc. Oncology (Williston Park, NY) 2008;22(2 Suppl Nurse Ed):1318; discussion 19.

    • Search Google Scholar
    • Export Citation
  • 9.

    Bevans M, Wehrlen L, Prachenko O. Distress screening in allogeneic hematopoietic stem cell (HSCT) caregivers and patients. Psychooncology 2011;20:615622.

    • Search Google Scholar
    • Export Citation
  • 10.

    Braamse AM, van Meijel B, Visser O. Distress, problems and supportive care needs of patients treated with auto- or allo-SCT. Bone Marrow Transplant 2014;49:292298.

    • Search Google Scholar
    • Export Citation
  • 11.

    Ransom S, Jacobsen PB, Booth-Jones M. Validation of the Distress Thermometer with bone marrow transplant patients. Psychooncology 2006;15:604612.

    • Search Google Scholar
    • Export Citation
  • 12.

    Efficace F, Gaidano G, Breccia M. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol 2015;168:361370.

    • Search Google Scholar
    • Export Citation
  • 13.

    Kendall J, Glaze K, Oakland S. What do 1281 distress screeners tell us about cancer patients in a community cancer center? Psychooncology 2011;20:594600.

    • Search Google Scholar
    • Export Citation
  • 14.

    Steensma DP, Heptinstall KV, Johnson VM. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res 2008;32:691698.

    • Search Google Scholar
    • Export Citation
  • 15.

    LeBlanc TW. Addressing end-of-life quality gaps in hematologic cancers: the importance of early concurrent palliative care. JAMA Intern Med 2016;176:265266.

    • Search Google Scholar
    • Export Citation
  • 16.

    Nickolich M, El-Jawahri A, LeBlanc TW. Palliative and end-of-life care in myelodysplastic syndromes. Curr Hematol Malig Rep 2016;11:434440.

  • 17.

    Efficace F, Gaidano G, Breccia M. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. Lancet Oncol 2015;16:15061514.

    • Search Google Scholar
    • Export Citation
  • 18.

    Abel GA, Efficace F, Buckstein RJ. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica 2016;101:781788.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 308 238 12
PDF Downloads 148 114 7
EPUB Downloads 0 0 0